Adverse drug reactions of cefoperazone sodium and sulbactam sodium in children

doi:10.19803/j.1672-8629.2022.05.13

Abstract

Abstract: Objective To analyze the characteristics of adverse drug reactions (ADR) of cefoperazone sodium and sulbactam sodium in children, and to provide data for clinical decision-making. Methods ADR reports of cefoperazone sodium and sulbactam sodium in children in Henan Pediatric Medical Alliance between 2014 and 2018 were collected. The gender, age distribution, types of ADR and involved systems and organs were analyzed. Results A total of 877 reports were collected, 536 of which involved males and 341 involved females. There were 50 reports related to the neonatal group (5.70%), 126 the 1-12-month-old group (14.37%), 319 the 1-3-year-old group (36.37%), 208 the pre-school age group (23.72%), 95 the school-age group (10.83%), and 79 related to the adolescent group (9.01%). The peak of ADR occurred between the day of administration and the third day. There were 83 reports (0.95%) on serious cases, and the proportion of severe ADR in the pre-school age group was the highest (3.42%). The clinical manifestations of ADR in children were mainly skin lesions (65.90%) and digestive system lesions (20.07%), and hematological system lesions were rarely reported (0.98%). Severe ADR included severe skin rash, convulsions and epilepsy. Conclusion There is something unique about ADR of cefoperazone sodium and sulbactam sodium in children, which is worthy of attention in clinic.

Key words: cefoperazone sodium and sulbactam sodium, adverse drug reaction, children

CLC Number:

R994.11

LI Yan, SUN Chong, LYU Meng, ZHOU Yuxue, MA Shuli. Adverse drug reactions of cefoperazone sodium and sulbactam sodium in children[J]. Chinese Journal of Pharmacovigilance, 2022, 19(5): 537-540.

References

[1] SHEN XM, WANG WP.Pediatrics(儿科学)[M]. 7th ed. Beijing: People's Medical Publishing House, 2011: 3.
[2] National Center for ADR Monitoring. WHO adverse reaction terminology (WHO 药品不良反应术语集)[M]. Beijing: China Medical Science and Technology Press, 2003.
[3] ZHANG LL, SONG HT.Retrospective analysis on 328 adverse drug reaction reports from department of pediatrics in a grade 3 and first-class hospital from 2013 to 2017[J]. Chinese Journal of Drug Application and Monitoring(中国药物应用与监测), 2019, 16(1): 32-35.
[4] PAN WW, NI SQ, LI CM, et al. A s urvey of public perception on clinical research in children[J]. Chinese Journal of Hospital Administration(中华医院管理杂志), 2017, 33(1): 75-78.
[5] XIA MQ, BI J, ZHANG YF.Pharmaceutical care for one pediatric patient with drug hypersensitivity syndrome[J]. Journal of Pediatric Pharmacy(儿科药学杂志), 2018, 24(7): 39-42.
[6] LIU C, XU HM, TAN LP, et al.Clinical analysis of drug hypersen-sitivity syndrome in 22 children[J]. J Clin Pediatric(临床儿科杂志), 2017, 35(7): 522-524.
[7] KAMIJIMA M, WANG H, YAMANOSHITA O, et al.Occupational trichlor-oethylene hypersensitivity syndrome: human herpesvirus 6 reactivation and rash phenotypes[J]. J Dermatol Sci, 2013, 72(3): 218-224.
[8] UNO H, KABASHIMA K, TOHYAMA M, et al.TNF-α as a useful predictor of human herpesvirus-6 reactivation and indicator of the disease process in drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS)[J].J Dermatol Sci, 2014, 74(2): 177-179.
[9] OGAWA K, MORITO H, HASEGAWA A, et al.Elevated serum thymus and activation-regulated chemokine (TARC/CCL17) relates to reactivation of human herpesvirus 6 in drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS)[J]. Br J Dermatol, 2014, 171(2): 425-427.
[10] TANG XY, LI Y, MA K, et al.Clinical analysis of drug-induced hypersensitivity syndrome in 26 children[J]. Chin J Derma Venereol(中国皮肤性病学杂志), 2019, 33(6): 679-693.
[11] HUA X, LIU HJ, ZHANG M, et al.Clinical analysis of 55 cases of drug reaction with eosinophilia and systemic symptoms[J].Chin J Derma Venereol(中国皮肤性病学杂志), 2015, 29(3): 262-264.
[12] SHIOHARA T, KANO Y.Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and manag-ement[J]. Expert Opin Drug Saf, 2017, 16(2): 139-147.
[13] KARDAUN SH, SIDOROFF A, VALEYRIE-ALLANORE L, et al.Variability inthec-linical pattern of cutaneous side effects of drugs with systemic symptoms: does a DRESS syndrome really exist?[J]. Br J Dermatol, 2007, 156(3) : 609-611.
[14] CRIADO PR, CRIADO RF, AVANCINI JM, et al.Drug reaction with eosinophilia and systemic symptoms (DRESS) / drug-induced hypersensitivity syndrome (DIHS): a review of current concepts[J]. An Bras Dermatol, 2012, 87(3) : 435-449.
[15] CHIOU CC, YANG LC, HUNG SI, et al.Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan[J]. J Eur A Card Dermatol Venereol, 2008, 22(9) : 1044-1049.
[16] MARTINEZ-RODRIGUEZ JE, BARRIGA FJ, SANTAMARIA J, et al.Noncon-vulsive status epflepticus associated with cephalosporins in patients with renal failure[J]. Am J Med, 2001, 111(2): l15-l19.
[17] YANG J, LIU LH, YANG H.Two cases of epilepsy form seizure caused by cefoperazone sodium and sulbactam sodium[J]. Journal of Clinical Pharmacotherapy(临床药物治疗杂志), 2017, 15(12): 49-50, 54.
[18] ZHANG JA, WANG HL, GUO JP, et al.One case of epilepsy induced by Cefoperazone/sulbactam[J]. China Pharmacist(中国药师), 2011, 14(11): 1664-1665.
[19] YANG JZ, XIONG JH, CHEN DW, et al.Analysis of influence factors of adverse reactions of the nervous ssystem caused by cefoperazone/ sulbactam[J]. Chin J Pharmacoepidemiol(药物流行病学杂志), 2016, 25(9): 563-567.
[20] WALLACE KL.Antibiotic-induced convulsions[J]. Crit Care Clin, 1997, 13(4): 741-762.
[21] FAN QE, YE F, LYU GH, et al.One case of epilepsy induced by cefoperazone and sulbactam[J]. China Pharmacist(中国药师), 2018, 21(10): 1819-1820.
[22] SCHÄFER H, NABER K, ADAM D. Hemostasis disturbance caused by cephalosporins with an N-methylthiotetrazole side chain: a randomized pilot study[J]. Arzneimittel-forschung, 1989, 39(9): 1156-1162.
[23] SHEARER MJ, BECHTOLD H, ANDRASSY K, et al.Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status[J]. J Clin Pharmacol, 1988, 28(1): 88-95.
[24] ZHANG LL, MA LY, CHEN CY, et al.Case report analysis of thrombocytopenia induced by cefoperazone sodium/sulbactam sodium in patient with chronic kidney disease[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2019, 35(11): 1186-1188.
[25] SHAO XM, YE HM, QIU XS.Practice of Neonatology(实用新生儿学)[M]. 4th ed.Beijing: People's Medical Publishing House, 2016: 633.
[26] Pediatrics Group of Microecology Branch of Chinese Preventive Medicine Association. Evidence-based guidelines to the clinical application of probiotics in pediatrics[J]. Chinese Journal of Practical Pediatrics(中国实用儿科杂志), 2017, 32(32): 81-90.